Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $107.67B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: GSK stock price vs PTCT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PTCT's multiple
Needs PTCT P/E.
Implied fair value · at GSK's multiple
Needs GSK P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GSK FY 2025 (ended Dec 31, 2025) · PTCT FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 71% equity / 29% debt · EV / Revenue 3.71x · EV / EBITDA 19.25x
Capital structure 95% equity / 5% debt · EV / Revenue 2.38x · EV / EBITDA 5.50x
GSK carries the larger enterprise value at $163.78B against $4.13B; PTCT trades on the lower EV / Revenue multiple (2.38x vs 3.71x); PTCT on the lower EV / EBITDA (5.50x vs 19.25x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GSK plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
PTC Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
-1.40x
Net debt / EBITDA
Leverage against operating earnings
6.59x
-2.21x
Cash and equivalents
Liquid reserves on the balance sheet
$3.40B
$1.95B
Total debt
Interest-bearing obligations outstanding
$44.87B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
GSK vs PFE
ELI LILLY & Co
GSK vs LLY
BRISTOL MYERS SQUIBB CO
GSK vs BMY
JOHNSON & JOHNSON
GSK vs JNJ
AbbVie Inc.
GSK vs ABBV
AMGEN INC
GSK vs AMGN
VERTEX PHARMACEUTICALS INC / MA
GSK vs VRTX
Sarepta Therapeutics, Inc.
GSK vs SRPT
BIOMARIN PHARMACEUTICAL INC
GSK vs BMRN
ALNYLAM PHARMACEUTICALS, INC.
GSK vs ALNY
$286.63M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
